Dashboard
1
The company has declared negative results in Dec'2024 after 4 consecutive positive quarters
- NET PROFIT(HY) At SEK -108.8 MM has Grown at -1,233.33%
- OPERATING CASH FLOW(Y) Lowest at SEK -438 MM
- INTEREST(HY) At SEK 37.6 MM has Grown at 149.01%
2
Risky -
3
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
SEK 694 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
0.60
-24.95%
0.34
Revenue and Profits:
Net Sales:
9 Million
(Quarterly Results - Jun 2025)
Net Profit:
-81 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.0%
0%
-2.0%
6 Months
-6.67%
0%
-6.67%
1 Year
-17.51%
0%
-17.51%
2 Years
-81.0%
0%
-81.0%
3 Years
-87.61%
0%
-87.61%
4 Years
-95.63%
0%
-95.63%
5 Years
-58.63%
0%
-58.63%
Doxa AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.76%
EBIT Growth (5y)
-334.60%
EBIT to Interest (avg)
-1.41
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.59
Sales to Capital Employed (avg)
0.00
Tax Ratio
0.01%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0.77%
ROE (avg)
0.76%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.31
EV to EBIT
-4.85
EV to EBITDA
-5.49
EV to Capital Employed
0.60
EV to Sales
129.74
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-12.41%
ROE (Latest)
-22.01%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
8.80
2.50
252.00%
Operating Profit (PBDIT) excl Other Income
-7.40
-22.00
66.36%
Interest
18.10
19.50
-7.18%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-80.60
-28.20
-185.82%
Operating Profit Margin (Excl OI)
-6,965.90%
-8,880.00%
191.41%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 252.00% vs 0.00% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -185.82% vs 96.65% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
15.50
9.90
56.57%
Operating Profit (PBDIT) excl Other Income
-540.40
-30.70
-1,660.26%
Interest
22.50
2.10
971.43%
Exceptional Items
-1,221.10
302.10
-504.20%
Consolidate Net Profit
-1,723.30
291.90
-690.37%
Operating Profit Margin (Excl OI)
-34,877.40%
-3,303.00%
-3,157.44%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 56.57% vs 90.38% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -690.37% vs 831.58% in Dec 2023
About Doxa AB 
Doxa AB
Pharmaceuticals & Biotechnology
Doxa AB is a Sweden-based company which develops products based on bio-active ceramics. The Company develops, manufactures and commercializes products based upon its technology platform of calcium aluminate hydrate and bioactive ceramics. Activities are divided into the therapy areas of orthopedics and odontology. Research areas within orthopedics are methods for treating fractures resulting from osteoporosis, reconstructive orthopedics and coating of implants. Research areas within odontology are tooth restoration and implant fixation.
Company Coordinates 
Company Details
Axel Johanssons Gata 4-6 , UPPSALA None : 754 50
Registrar Details






